Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Chikungunya Vaccines

Chikungunya fever vaccines protect against infection with the chikungunya virus.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

IXCHIQ

Chikungunya-Impfstoff (lebend, attenuiert)

Verwendung ab einem Lebensalter von 18 Jahren / Use from 18 years of age onwards

Valneva Austria GmbH

 Mono EU/1/24/1828 28.06.2024

EPAR: IXCHIQ

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 527 in BAnz AT 12.03.2025 B3.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 14.03.2025